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Magnetic nanoparticles have been used as effective vehicles for the targeted delivery of therapeutic
agents that can be controlled in their concentration and distribution to a desired part of the body by
using externally driven magnets. This study focuses on the synthesis, characterization, and functionali-
zation of pullulan–spermine (PS) magnetic nanoparticles for medical applications. Magnetite nano-
powder was produced by thermal decomposition of goethite (FeOOH) in oleic acid and 1-octadecene;
pullulan–spermine was deposited on the magnetite nanoparticles in the form of pullulan–spermine
clusters. EGFP-p53 plasmid was loaded on functionalized iron oleate to transfer into cells. Synthesized
nanoparticles were characterized by Fourier transform infrared spectroscopy (FTIR), dynamic light
scattering (DLS), vibrating sample magnetometry (VSM), and transmission electron microscopy (TEM).
The encapsulation efﬁciency and drug loading efﬁciency of the nanocomplexes were tested. FTIR studies
showed the presence of oleic acid and 1-octadecene in the iron oleate nanopowder and veriﬁed the
interaction between spermine and pullulan. The characteristic bands of PS in the spectrum of the pull-
ulan–spermine-coated iron oleate (PSCFO) conﬁrmed that PS covered the surface of the iron oleate
particles. TEM studies showed the average size of the iron oleate nanopowder, the PSCFO, and the
plasmid-carrying PSCFO (PSCFO/pEGFP-p53) to be 34712 nm, 100750 nm and 17273 nm, respec-
tively. Magnetic measurements revealed that magnetic saturation of the PSCFO was lower in comparison
with the iron oleate nanopowder due to the presence of organic compounds in the former. In cytotoxicity
tests performed using U87 cells as glioblastoma cells, a 92% survival rate was observed at 50 mg/ml of the
plasmid-carrying PSCFO, with an IC50 value of 189 mg/ml.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Cancer is commonly treated with a combination of surgery,
radiation therapy, chemotherapy, and photodynamic therapy
(PDT) [1]. While chemotherapy is an effective treatment, the side
effects of its toxicity are often severe and devastating when de-
livered as a full body dose to the patient. Recent developments
employing nanotechnology have made it possible to deliver a drug
to the targeted tissue across biological barriers, and to release it atCentre, Faculty of Pharmacy,
oulevard, PO Box 76175-439,
inejad),
hani), mansari@kmu.ac.ir,a controlled rate that minimizes cell and tissue degradation [2]. In
this regard, magnetic nanoparticles have shown great potential in
targeted drug delivery for cancer treatment [3]. For example,
magnetic nanoparticles coated with activated carbon are able to
transport pharmaceuticals to a speciﬁc site in the body when fa-
cilitated by an external magnetic ﬁeld. This allows more con-
centrated doses of drugs to be delivered to relevant cells, and kept
on site longer. Chemical and physical vapor deposition and me-
chanical attrition are used in the preparation of nanoparticles [4]
where homogeneity, particle size and size distribution, morphol-
ogy, and agglomerate size are the most important parameters in
product speciﬁcation [5]. The thermodynamically equilibrated
state of the particles is restored by condensation of nuclei of the
reaction product, and controlled by the kinetics of the nucleation
and growth [6]. Kinetic factors (e.g. reaction rates, transport rates
of reactants, and the removal and redistribution of matter) control
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The reaction and transport rates are affected by the temperature,
pH and mixing of the reactants, as well as their respective con-
centrations. Particle morphology is inﬂuenced by factors such as
supersaturation, colloidal stability, nucleation and growth rates,
recrystallization, and aging times [8]. In particular, supersaturation
has a dominant role in determining the morphology of precipitates
[9]. To prevent dangerous agglomeration of the particles in the
blood stream, magnetic nanoparticles must be tailor-made [10] to
avoid agglomeration of particles occurring during drying, hand-
ling, and post-processing [11]. In this regard, surfactants can help
control particle dispersion during chemical synthesis [12]. Another
aspect requiring attention in the synthesis of nanoparticles is the
annealing process which causes an increase in crystallinity, that in
turn greatly affects the magnetic and electronic properties of
particles [13]. Molecular weight, surface charges, amphiphilicity,
as well as the structure and shape of particles, also affect the ef-
ﬁciency of gene transfection through polymer-based vectors [14].
While cationic polymers such as polyethyleneimine (PEI), poly L-
lysine (PLL), chitosan, and polyamidoamines (PAMAM) are com-
monly used in gene delivery [15], pullulan–spermine complexing
with plasmid DNA has been shown to be a potent carrier system
for non-viral gene therapy [16]. Such complexes are known to
undergo cellular endocytosis via clathrin-dependent endocytosis
[17]. Pullulan is recognized by the asialoglycoprotein receptor
(ASGPR) found primarily in the liver, but cells which do not ex-
press ASGPR are also able to internalize pullulan–spermine [16,18].
Oncogenes and tumor suppressor genes are the two main types of
genes that play a role in cancer [19,20]. Tumor suppressor genes
have been found, including TP53 (p53), BRCA1 and BRCA2 (for
breast cancer), APC (colorectal tumors) and RB1 (retinoblastoma)
[21]. Abnormalities of the TP53 gene have been found in more
than half of human cancers [22]. The p53 protein is involved in the
pathway to apoptosis and a cell with DNA damage that cannot be
repaired continue to grow and divide, and then lead to cancer
[23,24]. The outcomes of common cancer therapy for malignant
glioblastoma are still very poor with less than 5% of patients sur-
viving ﬁve years post diagnosis even with the best current treat-
ment [25]. Bearing all this in mind, we hypothesized that the in-
corporation of magnetic nanoparticles to pullulan–spermine gene
delivery nanocarriers could promote effective cellular uptake via a
targeting delivery system. Hence, the main aim of this study was
to develop a chemically modiﬁed magnetic nanoparticle vector for
gene delivery systems to improve their targeting gene therapy.
Accordingly, magnetic nanoparticles were prepared and char-
acterized by FTIR, DLS, VSM, and TEM techniques. Their cytotoxi-
city in the human glioblastoma cell line U87 and their ability to
protect genes from physical, chemical, and enzymatic degradation
were evaluated. Finally magnetic nanoparticles were experienced
against glioblastoma cell line, U87, to show their therapeutic ef-
ﬁcacy in vitro and in vivo experiments.2. Experimental
Goethite (FeOOH), 1-octadecene, spermine, pullulan, carbo-
nyldiimidazole (CDI), Dulbecco's modiﬁed eagle's medium F12
(DMEM), fetal bovine serum (FBS), penicillin–streptomycin
(100 μg/ml), phosphate-buffered saline (PBS), 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetra-
zolium (WST-1 reagent), poly vinyl alcohol (PVA), and dimethyl
sulphoxide (DMSO) were purchased from the Sigma Aldrich
Company (Mo, USA). Dimethyl formamide (DMF) and oleic acid
were obtained from the Merck Company (Darmstadt, Germany).
The GeneJET Plasmid Miniprep Kit was obtained from Thermo
Scientiﬁc while U87 glioblastoma cells were obtained from thePasteur Institute of Iran.
2.1. Construction of plasmid
The construction of the pEGFP-p53 vector (5.89 kb) coding for
the enhanced green ﬂuorescent protein (EGFP), which contained
the tumor protein p53 gene that acts as a tumor suppressor, was
undertaken based on methods previously described [26]. The full-
length 1191 bp tumor protein p53 (Tp53) gene (GenBank
AAD28628.1) that encodes 397 amino acids was synthesized using
a DNA synthesizer and sub-cloned into the pBR322 vector using
the PstI and BamHI sites. The recombinant pBR322-p53 plasmid
containing the Tp53 gene was veriﬁed by restriction enzyme di-
gestion and sequencing. The Tp53 was then sub-cloned into the
pEGFP-N1 vector, and the digested products of the recombinant
plasmid were veriﬁed by agarose gel electrophoresis. Then pEGFP-
p53 was propagated in an Escherichia coli strain Top 10 (ATCCs
PTA-10989™) and puriﬁed by the GeneJET Plasmid Minipreps Kit
according to the manufacturer's protocol. Both the yield and purity
of the pEGFP-p53 were evaluated by UV spectroscopy. The absor-
bance ratio at wavelengths of 260–280 nm for DNA solution was
between 1.8 and 2.0 after dilution to between 1:500 and 1:1000 in
TE buffer.
2.2. Synthesis of magnetite nanoparticles
The synthesis of magnetite nanoparticles (Fe3O4) basically fol-
lowed the procedure reported by Colvin [27]. Magnetite nano-
crystals were synthesized in a three-neck ﬂask equipped with a
condenser, magnetic stirrer, thermocouple, and heating mantle.
Typically, a mixture of 0.178 g FeOOH ﬁne powder (2.00 mmol),
2.26 g oleic acid (8.00 mmol) and 5.00 g 1-octadecene (20 mmol)
was heated with stirring to 320 °C and maintained at this tem-
perature for 1 h. On completion of the reaction, the product was
allowed to cool to room temperature and 30 ml ethanol was ad-
ded. The resulting black precipitate was separated by centrifuga-
tion at 6300 g for 20 min. During this time the supernatant turned
from turbid black to clear brown as the iron source material dis-
solved and formed an iron carboxylate salt. The reaction was
protected under argon in order to avoid any undesired side-reac-
tions (e.g. oxidation of oleic acid).
2.3. Preparation of pullulan–spermine (PS)
Spermine was introduced to the hydroxyl groups of pullulan by
a CDI activation method [28]. Pullulan (25 mg) was dissolved in
2.5 ml DMSO and 435 mg of CDI was then added to reach a molar
ratio of 3:1 for CDI to the hydroxyl groups of pullulan. The CDI–
pullulan mixture was incubated for 5 min at room temperature.
Spermine (2500 mg) was dissolved in 22.5 ml DMSO was added
drop-wise to reach a large molar excess of spermine in order to
prevent cross linking of pullulan. The mixture was then incubated
overnight at 40 °C and puriﬁed by dialysis in deionized water.
2.4. Surface functionalization of nanoparticles
Pullulan–spermine-coated iron oleate (PSCFO) was prepared by
a solvent diffusion method. Wet magnetite gel (50 mg) and
100 mg of pullulan–spermine were dissolved in separate 5 ml
portions of DMF and the two portions were mixed using a vortex
mixer. The resulting mixture was then added to 90 ml of PVA
(0.5%, w/w) by means of a syringe that was positioned with the
needle directly in the medium, with moderate mechanical stirring.
The magnetic particles were isolated by ultracentrifugation at
29,000g for 20 min at 4 °C and washed three times with deionized
water before freeze-drying for later characterization.
T. Eslaminejad et al. / Journal of Magnetism and Magnetic Materials 402 (2016) 34–43362.5. Preparation of polyion complexes
To prepare polyion complex (PIC) micelles, 25 ml of PSCFO and
PS (10 mg/μl in deionized water) was mixed with an equal volume
of pEGFP-p53 plasmid DNA (0.1 mg/ml). The PIC composition was
calculated on the basis of nitrogen number of pullulan–spermine
(N) per phosphorus number of plasmid DNA (P) and expressed as
the N/P ratio.
2.6. Characterization of nanoparticles
FTIR spectra of iron oleate, PS, and PSCFO were recorded as KBr
discs in the range 3500–500 cm1 on Bruker Optics' RockSolid™
design. The mean particle size and the size distribution of the
nanoparticles were determined by photon correlation spectro-
scopy (PCS). The zeta potential values of the nanoparticles were
obtained by laser doppler anemometry (LDA) that measured the
mean electrophoretic mobility. Samples of iron oleate, PS, and
PSCFO, PS/pEGFP, and PSCFO/pEGFP suspensions were diluted at
the appropriate concentrations with ﬁltered water for PCS and
LDA. PCS and LDA analyses were performed with a Zetasizers
3000 HS particle size analyzer (Malvern Instruments, UK). Light
scattering measurements were made in triplicate on samples that
were sufﬁciently diluted to prevent multiple scattering. Nano-
particle morphology, size distribution, and average particle dia-
meter were investigated by TEM in both the secondary and the
backscattered electron modes using a Zeiss EM10C transmission
electron microscope operated at 80 kV accelerating voltage. For
TEM studies, samples of the iron oleate, PS, PSCFO, PS/pEGFP-p53,
and PSCFO/pEGFP-p53 were suspended in acetone and sonicated
for 30 min. A 10 ml drop of the sample was adsorbed on to a for-
mvar carbon coated grid Copper Mesh 300. After 5 min, excess
liquid was wicked with ﬁlter paper, and the sample was loaded
into the vacuum stage of the microscope and visualized. Size dis-
tribution and average particle diameter were determined analyz-
ing 5–10 images, representing a population of more than 2000
particles. The content of iron oleate in the PSCFO was determined
by using a BAHR STA 503 thermoanlyzer. Samples weighing be-
tween 5 and 15 mg were heated from 10 to 800 °C at a heating rate
of 10 °C/min in air. The magnetic properties of nanoparticles were
measured at room temperature (RT) using a VSM-7300 vibrating
sample magnetometer (VSM) (Meghnatis Daghigh Kavir Co., Ka-
shan, Iran) in a maximum applied ﬁeld of 10 kOe. Samples were
attached with a glass rod to the vibrator using Teﬂon coupling. The
vibration was along the z-axis with ﬁxed amplitude of 5 mm and
frequency of 23 Hz. The magnetic ﬁeld was applied along the x-
axis by means of an electromagnet capable of producing ﬁelds up
to two Tesla. The magnetic moment of the vibrating sample in-
duced an electromotive force in the pick-up coils arranged along
the x-axis. A standard nickel sample was used to calibrate the
system. Magnetization curves for samples were used to analyze
the results. From the hysteresis loops obtained, the saturation
magnetization (Ms), remnant magnetization (Mr), and coercivity
(Hc) were determined.
The bonding of pEGFP-p53 to PS and PSCFO was studied by
agarose gel electrophoresis run for 30 min at 100 V (Sub-Cell GT
96/192, Bio-Rad Laboratories Ltd., England), followed by ethidium
bromide (EtBr) staining. The capture of DNA on to the polymer was
examined to evaluate its condensation ability. A blank comprising
a complex of pEGFP-p53 (20 μg/ml) and EtBr (0.4 mg/ml) was used
to calibrate to 100% ﬂuorescence. The ﬂuorescence intensity of the
samples (excitation: 510 nm, emission: 590 nm) was measured
15 min later using a spectroﬂuorophotometer (RP-5000; Shi-
madzu, Japan). The results were expressed as relative ﬂuorescence
intensity (percent decrease against the pEGFP-p53-EtBr complex).
Sample ﬂuorescence was determined after subtracting thebaseline ﬂuorescence of EtBr in the absence of the DNA. The re-
lative ﬂuorescence was based on two independent experiments
and calculated using the following Eq. (1) [29]:
= ( − − ) × ( )( + )% Relative Fl. Fl. Fl. /Fl. Fl. 100 1Obs EtBr pDNA EtBr EtBr
where Fl.Obs is the ﬂuorescence intensity of complex; Fl.EtBr is the
ﬂuorescence of EtBr alone; Fl.(pDNAþEtBr) is the ﬂuorescence of
pDNAþEtBr.
To discriminate between DNA adhesion to the carrier and ac-
tual incorporation, extracellular ﬂuorescence was examined with
an Olympus TH 1400 ﬂuorescence microscope (254 nm wave-
length) which was quenched by the addition of trypan blue
(0.2 mg/ml, pH 4.4) to PS/pEGFP-p53 and PSCFO /pEGFP-p53 [30],
the non-quenched fraction thus representing encapsulated DNA.
2.7. Electrophoretic nuclease resistance and stability assays
To investigate the ability of the copolymer to protect DNA from
enzymatic degradation, 3 ml of naked pEGFP-p53, PS/pEGFP-p53,
and PSCFO/pEGFP-p53 (containing 0.75 mg plasmid) were com-
bined with 2 U DNase I in 4 ml 50 mM Tris–HCl/10 mMMgCl2 at pH
7.4. After incubation for 1 h at 37 °C, the sample was run on an
agarose gel and visualized using a UV image capture system.
Naked pEGFP-p53 served as a negative control. For stability assays,
PS/pEGFP-p53 and PSCFO/pEGFP-p53 complexes (7%) were pre-
pared and incubated in serum-free medium for up to 7 days. The
ﬂuorescent intensity of bands corresponding to DNA and their
electrophoretic mobility were observed and compared with those
obtained with naked pEGFP-p53 and PS/pEGFP-p53, and PSCFO/
pEGFP-p53 complexes in the absence of serum-free medium.
2.8. In vitro release of DNA
To quantify the DNA release from the nanostructured systems,
4 mg of PS/pEGFP-p53 and PSCFO/pEGFP-p53 nanoparticles were
incubated in PBS (pH 7.4, 37 °C) with gentle magnetic stirring for
72 h. Samples were centrifuged for 10 min at 16,000g and the
supernatant was removed and replaced with fresh buffer. At ﬁxed
time points (5, 9, 18, 23, and 30 days), supernatant was collected,
analyzed by spectrophotometry, and the kinetics of DNA release
from samples were assessed. All measurements were carried out
in triplicate.
2.9. Cell culture
Non-transformed U87 cells were maintained in DMEM sup-
plemented with 10% FBS and 100 mg/ml penicillin/streptomycin at
37 °C; 5% CO2.
2.10. Cytotoxicity assay
To seed cells for the cytotoxicity assay, trypsinized U87 cells
were ﬁrst re-suspended in the cell culture medium at a density of
2105 cells/ml. After incubating the cells for 24 h, the medium
was changed to a fresh serum-free medium, and 100 ml of the
prepared magnetic transfection complexes of each concentration
(0, 50, 75, 100, 250 and 500 mg/μl) were applied to each well of an
ELISA plate. The plates were then incubated at 37 °C; 5% CO2 for
24 h. The medium was subsequently changed to DMEM and 10 ml
of WST-1 solution was added, and the cells were allowed to in-
cubate for 3 h. The absorbance of samples was measured by an
ELISA reader (BioTeks Elx 800) at 450 nm with the reference at
630 nm. Cell viability was expressed as 100% for control, non-
treated cells. All samples were run in three replicates and the
experiments were repeated twice. The survival rate (%) was
T. Eslaminejad et al. / Journal of Magnetism and Magnetic Materials 402 (2016) 34–43 37calculated following equation (2) [31]:
= ( )
× ( )
% Survival rate OD in treatment group/OD in control group
100 2
The inhibitory concentration required for 50% cytotoxicity
(IC50) value was determined using the Prism dose-response curve
(Prism Graphpad, Prism version version 6 for windows, GraphPad
Software, Sa Diego, CA, USA), and plotting the percentage of in-
hibition versus the concentration.3. Results and discussion
In this study, magnetic pullulan–spermine (PS) nanoparticles
were prepared and evaluated as possible carriers for therapeutic
agents. A plasmid comprising the pEGFP-p53 vector containing the
tumor protein p53 gene served as a model curative transported by
the nanoparticles. Although the thermal decomposition method of
preparing Fe3O4 has many advantages for producing highly
monodispersed particles with a narrow size distribution, it has,
nevertheless, a signiﬁcant disadvantage in that the resulting par-
ticles are generally soluble only in nonpolar solvents [32].
The ratios of the starting reagents including the organometallic
compounds (goethite), surfactant (oleic acid), and solvent (1-oc-
tadecence) together with the reaction temperature and reaction
time are the main parameters for controlling nanoparticle synth-
esis. The original red color of the hematite (α-Fe2O3) gradually
changed to brown as the reaction process proceeded and led to the
disappearance of the hematite diffraction peaks. Finally, the color
of the reactant changed from brown to black as a result of the
decomposition of iron oleate and the formation of nanoparticles.
FTIR analyses showed that the magnetite (Fe3O4) was completely
covered by fatty acid [33].
Goethite powder is generally stable in air and is extremely cost-
effective compared to their organometallic compounds [34]. The
magnetic structure of the surface layer is usually different from
that in the body of nanoparticle, and the magnetic interactions in
the surface layer could have a notable effect on the magnetic
properties of nanoparticles. Therefore, the interaction between theFig. 1. FTIR spectra of iron oleatsurfactant and the nanoparticle is critical to synthesis and appli-
cation of nanoparticles. Oleic acid is known to provide a good
protective surfactant for oxide-based nanoparticles [35]. It is used
to stabilize the magnetic nanoparticles with strong chemical
bonding between the carboxylic acid and the amorphous iron
oxide nanoparticles. In this regard, oleic acid as a biologically safe
molecule covered the surface of the Fe3O4 to control their particle
size, prevent aggregation, achieve biocompatibility, and increase
lipophilicity and stability [36]. Recently, black copolymers have
been used for the formation of shells for encapsulation of nano-
particles. They promote particle interaction, solubility, and po-
tentially a uniform shape of the core shell nanoparticles. The hy-
drophobic chains of the octadecence magnetic block are able to
interpenetrate the surface-bound oleic acid ligands. X-ray analysis
show that 99.9% of the polymeric shells contain only a single na-
noparticle [37]. However, the naked iron oxide nanoparticles have
high chemical activity, and are easily oxidized in air, resulting in
the loss of magnetism and dispersibility. Therefore, it is very im-
portant to provide a proper surface coating and deploy effective
protection strategies to maintain the stability of magnetic iron
oxide particles. In our studies, surfactants, polymers, and biomo-
lecules, etc. were used for functionalization.
3.1. FTIR spectra
Fig. 1(a) shows infrared spectra of magnetic particles covered
with oleic acid. The absorption bands in region from 400 cm1 to
600 cm1 correspond to goethite. The presence of oleic acid is
obvious in the sample. The absorption bands at 2341 and
2360 cm1 refer to the CH2 groups in oleic acid and 1-octadecene.
Another band can be observed at 1632 cm1, which has been
shifted left from 1710 cm1 (C¼O bond asymmetric vibration).
This can be attributed to the carboxyl groups of oleic acid com-
bining with the iron atoms on the surface of iron oleate nano-
particles. This renders a partial single bond character of the C¼O
bond that weakens it and shifts the stretching frequency to a
lower value. Carboxyl groups of oleic acid are chemisorbed to the
surface. FTIR spectra of PS (Fig. 1(b)) conﬁrm the introduction of
spermine into pullulan, as indicated by the C¼O stretch ate (a), PS (b) and PSCFO (c).
Fig. 2. TGA (black) and DTGA (blue) thermograms of iron oleate and PSCFO nanoparticles. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 3. Magnetization curves of naked iron oleate and PSCFO.
Fig. 4. Magnetization vs. applied magnetic ﬁeld for naked iron oleate and PSCFO.
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1100 cm1 and N–H bend at 852 cm1. The absorption bands at
2939 cm1 are the strong CH2 bands characteristic of CH2 groups
that are present in pullulan and spermine. The absorption peak at
3384 cm1 arising from the stretching vibration of the hydroxyl
group is weaker in the spectrum of PS as compared to that in
pullulan. Comparing the FTIR spectra of iron oleate (Fig. 1(a)) and
that of PSCFO (Fig. 1(c)), the characteristic bands of PS appearing
near 2923, 1652, 1558, 1541, 1436 and 1094 cm1 in the spectrum
of the PSCFO conﬁrm that PS covered the surface of the
nanoparticles.
It can be seen that the intensity of the C–O stretching at
1709 cm1 is signiﬁcantly reduced in the iron oleate, and a new
peak centered at 1551 cm1 is formed. This result is consistent
with the formation of iron carboxylate bonds in the Fe3O4. The iron
oleate spectrum also shows evidence of vinyl C–H stretching at
2341 cm1 and 2360 cm1, indicating that the oleate ligand does
not transform to stearate during the synthesis process. Finally, the
broad band at 400–600 cm1 is attributed to a stretching of the
Fe–O bonds. Iron carboxylates tend to form Fe3 (m3-O) clusters
which show one Fe–O stretching band in the Fe O3
III and two Fe–O
bands in the mixed-valence Fe Fe O2
III II . The results obtained in this
study are consistent with those reported by [38].
Fig. 5. TEM micrographs of nanoparticles prepared by thermal decomposition method. Iron oleate before functionalization (A), iron oleate after functionalization by PS in
two magniﬁcations 100, 35 nm (B and C).
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TGA and DTGA of iron oleate and PSCFO nanocomposites are
shown in Fig. 2. The thermogram of iron oleate and PSCFO shows
that the initial decomposition stage in the temperature range from
50 to 150 °C represents the water evolving (mass loss 8%). The
second decomposition event in the temperature range of 250–
350 °C with mass loss of 40% corresponds to the organic break-
down of PS polysaccharide chains, with total mass loss of up to
80% at 700 °C. Therefore, an estimate from the TGA curve esti-
mates the content of the Fe3O4 in the PSCFO to be about 20%. The
DTGA graph shows a peak at about 230 °C, and three to four peaks
in the range of 300–400 °C. Releasing of water began at about
40 °C and continued to 200 °C, and from about 200–500 °C, the
organic constituent in the organically modiﬁed layers began to
decompose.
3.3. Magnetic properties
Magnetization curves (M–H loop) for the iron oleate and PSCFO
measured at RT are presented in Fig. 3. At the maximum applied
magnetic ﬁeld of 10 KOe, the magnetization did not reach sa-
turation and no hysteresis loops could be observed (no remanent
magnetization and zero coercivity ﬁelds) [38]. The results in-
dicated that the iron oleate and PSCFO were superparamagnetic at
RT, with a calculated Ms of 14 and 9 emu/g respectively [39]. The
hysteresis loop analysis of the iron oleate and PSCFO at RT can be
used to conﬁrm the average size and particle size distribution of
iron oleate and PSCFO already obtained from DLS and TEManalyses. The decrease in saturation is ascribed to the size effect.
The magnetic particle size and size distribution could also be
calculated from the hysteresis curve using the following Eq. (3)
[39]:
( )( )( )ρ= π ( )D K T X M18 / / 3m B i s 1/3
where Xi is the initial magnetic susceptibility, Xi¼(dM/dH)H-0
which mainly arises from the largest particles, M is (mass) mag-
netization of particles, and H is magnetic ﬁeld strength, magne-
tizing force. ρ is the density of iron oleate (5.18 g/cm3), and KB is
Boltzmann constant.
The initial slope near the origin was determined from the
hysteresis plots by curve-ﬁtting the linear portion of the data.
Thus, the magnetic particle size, Dm, of samples was estimated to
be 9.4 and 10 nm for iron oleate and PSCFO, respectively. For su-
perparamagnetic particles, the true magnetic moment (m) at a
particular temperature can be calculated using the Langevin
equation (4) [40]:
( )( )= μ − μ ( )M M H K K T Hcot / T / 4s B B
where m¼MsπD3/6 is the true magnetic moment of each particle, D
the diameter of the particle, KB the Boltzmann constant, T the
absolute temperature (300 °K), and Ms is the saturation magneti-
zation. Fig. 4 shows the best ﬁt for the Langevin Eq. (4). From this
data ﬁt, the mean-magnetic moment per particle of sample was
found to be near two mB. Results show that the particles have ty-
pical superparamagnetic characteristics.
The MS value for the PSCFO was lower than that of the naked
Fig. 6. TEM micrographs of complexes prepared by solvent diffusion method. PS (A), PS/pEGFP-p53 (B), PSCFO/pEGFP-p53 (C).
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Dm was smaller than the particle size observed from TEM mea-
surement which was most likely due to contributions of a mag-
netically “dead layer” reported to be present on the surface of
particles [41].
3.4. Transmission electron microscopic studies
The morphology, structure, and size properties of iron oleate,
PSCFO, PS, PS/pEGFP-p53 and PSCFO/pEGFP-p53 were examined
by TEM.
Nanoparticles size measurements were processed using Image J
software. The average diameter of iron oleate nanoparticles was
34712 nm (δ¼35%). Fe3O4 nanoparticles were coated with oleic
acid as capping agent, rendering themwell-separated and stable in
non-polar solvents, they maintained their original cubic shape
with a good monodispersity (Fig. 5(A)). Iron oleate nanoparticles
that were coated by PS using microemulation method gave rise to
core–shell nanoparticles with a diameter of 100750 nm (δ¼50%).
Prepared nanocomposites were quite homogeneous in size, sepa-
rated and single-cored (Fig. 5(B and C)). However, some multi-core
nanoparticles fused together, but this was relatively uncommon.
Macroscopically, PS particles appeared as a long chain of in-
teracting particles composed of small nanoparticles with a calcu-
lated diameter of 166725 nm (δ¼15%) (Fig. 6(A)). Loading of
pEGFP-p53 on the PS (175717 nm, δ¼10%) nanoparticles resulted
in their appearing as long chain of interacting particles (Fig. 6(B)).
PSCFO/pEGFP-p53 (17273 nm, δ¼2%) nanoparticles resulted in
separated and single-cored (Fig. 6(C)).
The iron oleate had a highly porous structure as a result of thetopotactic transformation of goethite (FeOOH) to magnetite
(Fe3O4), which induced the formation of slit-shaped micropores
via the removal of water droplets generated during the reaction
process. Spherical monodispersed particles of 34 nm diameter that
were prepared had a narrow size distribution, indicating the par-
ticles were monodispersed. Using iron oleate as precursor in oc-
tadecence resulted in small monodispersed spherical particles
[42]. A slight aggregation can be observed which was due to the
aggregation of individual particles with an incomplete coating by
oleic acid molecules [43]. At 1–100 nm length scales, Brownian
motion leads to nanoparticle aggregation resulting in ‘local ag-
gregates’ of typical size 0.1–10 mm [44]. Iron oleate nanoparticles
were coated by pullulan–spermine to give rise to core–shell na-
noparticles. Prepared nanocomposites were quite homogeneous in
size, separated and single-cored (Fig. 5(B and C)). A polymer shell
allows dispersion of superparamagnetic iron oxide nanoparticles
in aqueous medium, but it could also allow for reversible ag-
gregation and dispersion [45]. PSCFO nanoparticles were nearly
spherical in shape and well-separated, but there was no signiﬁcant
change in size resulting from the PS coating process, as shown in
Fig. 5 (B and C).
3.5. Dynamic light scattering (DLS)
Hydrodynamic size readings of the synthesized nanoparticles
as determined by DLS are even more signiﬁcant than values ob-
tained by TEM for nanoparticles functionalized with long-chained
ligands. A mean hydrodynamic size value for iron oleate was
177718.3 nm (δ¼10.3%) versus 80.5718.5 nm (δ¼23%) for
PSCFO. Nanoparticles with hydrodynamic size more than 200 nm
Fig. 7. Gel retardation assay (agarose, 1%) of free EGFP-p53 plasmid (lanes 1–3),
PSCFO/pEGFP-p53 (lanes 4–6) and PS/pEGFP-p53 (lanes 7–9) (triplicate runs of the
same samples).
Fig. 8. Agarose gel electrophoresis of the DNA captured on nanoparticles. DNA
marker (1), DNase I digested PSCFO (positive control) (2), DNase I digested PSCFO/
pEGFP-p53 (3), DNase I digested PS/pEGFP-p53 (4), DNase I digested naked pEGFP-
p53 (negative control) (5).
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probably multicore nanocomposites. An average hydrodynamic
size of 200721 nm (δ¼10.3%) was shown for PS particles. At the
same time, pEGFP-p53 loaded on PS and PSCFO showed a mean
hydrodynamic size of 120743 nm (δ¼36%) and 179715 nm
(δ¼10%), respectively.
The average diameters determined by DLS were larger than the
sizes determined from the TEM images for the corresponding
samples. This was presumably because DLS gave the mean hy-
drodynamic diameter of the magnetite core surrounded by the
organic and solvation layers, whereas TEM gave the diameter of
magnetic nanoparticles alone in the dry state [46].
3.6. Colloidal stability
Colloidal stability of the nanoparticles plays a very signiﬁcant
role in relation to in vivo biomedical applications. Nanoparticle
zeta-potential at pH 7.4 was 3776 mV for iron oleate,
70726 mV for PS particles, 70726 mV for PSCFO,
69715 mV for pEGFP-p53 loaded on PS and 4378 mV for
pEGFP-p53 loaded on the PSCFO. Compared to uncoated magnetite
nanoparticles, pullulan–spermine coated particles were more
stable at the physiological pH of 7.4, reﬂecting the advantage of
such coating for nanoparticle stabilization.3.7. Gel retardation assay
Fig. 7 shows the migration of the free plasmid (lanes 1–3) and
the PSCFO/pEGFP-p53 and PS/pEGFP-p53 nanoparticles (lanes 4–
9). PSCFO/pEGFP-p53 and PS/pEGFP-p53 nanoparticles did not
display a strong ﬂuorescence. The smear band observed in lanes
7–9 suggested that a release of DNA might have occurred during
electrophoresis. A similar smearing was not observed in lanes 4–6,
leading to the hypothesis that strong electrostatic interactions
exist between PSCFO and pEGFP-p53, at least under the experi-
mental conditions used.
3.8. Ethidium bromide intercalation assay
The degree of DNA condensation was determined as a function
of the N/P ratio by an EtBr displacement assay. The incorporation
of DNA into PSCFO/pEGFP-p53 and PS/pEGFP-p53 nanoparticles
was monitored by following the ﬂuorescence emission of EtBr
intercalated into the DNA double helix. The results showed that
PSCFO and PS were able to achieve nearly complete quenching
(FI%¼18 and 0, respectively), indicating complete binding be-
tween PSCFO and PS and pEGFP-p53.
Fig. 9. Agarose gel electrophoresis of the nanoparticles encapsulating DNA. DNA
marker (1), PSCFO/pEGFP-p53 in serum-free medium (2), PSCFO/pEGFP-p53 in PBS
(3), PS/pEGFP-p53 in serum-free medium (4), PS/pEGFP-p53 in PBS (5).
Fig. 10. DNA release from the PSCFO/pEGFP-p53 and PS/pEGFP-p53 systems as
determined by spectrophotometry.
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The slight quenching effect induced by trypan blue suggested
that most of the loaded DNA had been encapsulated inside the
nanoparticles.
3.10. Electrophoretic nuclease resistance and stability assays
The ability of the copolymer to entrap the plasmid was studied
using the agarose electrophoresis technique. Following agarose gel
electrophoresis, Fig. 8 (lanes 3 and 4), no migration of free DNA
was observed, indicating that most of the DNA was captured by
the nanoparticles because of the high afﬁnity of PS for the DNA
[47,48]. Indeed, it is known that a strong electrostatic interaction
exists between the phosphate groups of DNA and the amino
groups of PS, as well as hydrophobic and hydrogen bonds.
The stability of PSCFO/pEGFP-p53 and PS/pEGFP-p53 com-
plexes (7%) was evaluated at 7 days in the serum-free medium and
in the absence of medium (PBS) (Fig. 9). The ﬂuorescence intensityof bands corresponding to DNA and their electrophoretic mobility
were observed and compared with those obtained with naked
DNA. The ﬂuorescence band was not localized in the well con-
taining the nanocomplexes, suggesting that the absence of DNA
binding to the surface of the nanoparticle. Moreover, no smear
bands were observed in lanes 2–5, suggesting that a release of
DNA would not have occurred during electrophoresis. Nano-
particle stability and nucleic acid protection are important para-
meters for efﬁcient nucleic acid delivery [49]. The results indicated
that the nanoparticles complexes were able to protect DNA at
supra physiological concentration of nuclease. Nuclease protection
is of great importance for gene delivery systems through main-
tenance of cargo bioavailability and improved pharmacokinetic
proﬁle, thereby increasing the therapeutic potential of these
nanoparticles.
3.11. DNA release studies
DNA release from the constructed systems was analyzed by
spectrophotometry. At ﬁxed time points of 5, 9, 18, 23, and 30 days
the supernatant was collected and the kinetics of DNA release
from PSCFO/pEGFP-p53 and PS/pEGFP-p53 complexes were mea-
sured (Fig. 10). The release of DNA from PSCFO/pEGFP-p53 nano-
particles showed an initial release within the ﬁrst 5 days and
continued during 9 days of incubation. Thereafter, the rate of re-
lease declined until the 23rd day. A slight increase in DNA release
was observed on day 30. No DNA release was observed from PS/
pEGFP-p53 nanoparticles in the ﬁrst ﬁve days. From day 9, the
release of DNA from the nanoparticle complex was observed until
the 30th day, yielding more than 25 mg of the encapsulated DNA.
3.12. Cytotoxicity assay
The cytotoxicity of various concentrations of nanoparticles
prepared in this study was evaluated after 24 h incubation of the
trypsinized U87 cells with the transfection complexes. The results
showed that as the concentration of PSCFO/pEGFP-p53 rose from
zero to 500 mg/ml on the basis of the initial concentration, the
survival rate of the U87 cells decreased. Both the primary effect of
the nanoparticles or their side effects could be responsible for the
observed cytotoxicity [50]. The broad spectrum of different na-
noparticles–cell interactions include an impact of nanoparticles on
the plasma membrane, nanoparticle-mediated intracellular traf-
ﬁcking, and nanoparticle-dependent perturbation of basic cellular
functions [51]. Therefore, a balance between cell membrane in-
tegrity and cytotoxicity of the therapeutic agent is a crucial aspect
in gene delivery. The survival rate with regard to cytotoxicity was
92% at 50 mg PSCFO/pEGFP-p53, with an IC50 value of 189 mg/ml, a
level similar to that reported previously [38].4. Conclusion
Magnetic (PSCFO) and nonmagnetic (PS) nanoparticles were
fabricated by thermal decomposition and solvent diffusion meth-
ods respectively. PSCFO nanoparticles were spherical in mor-
phology and 100 nm in mean diameter, with a unimodal size
distribution. The saturated magnetization of the iron oleate and
PSCFO nanoparticles reached 14 and 9 emu/g respectively, and
they showed superparamagnetic behavior at room temperature.
PSCFO nanoparticles displayed magnetite content and good bio-
compatibility. Hence, the new nanoparticles described here can be
developed for therapeutic applications in targeting tumors.
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